Answers are grounded in this paper and cite their sources.
The addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improved event-free survival among participants with locally advanced HNSCC. Neoadjuvant pembrolizumab did not affect the likelihood of surgical completion. No new safety signals were identified. (Funded by Merck Sharp and Dohme, a subsidiary of Merck [Rahway, NJ]; KEYNOTE-689 ClinicalTrials.gov number, NCT03765918.).
No takes yet. Share an insight, caveat, or question.
Uppaluri et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: